Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 402 participants.
Also called NCT01396395
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 402 participants
- Registry
-
NCT01396395
-
- Other papers using this trial's data
- Oral nicorandil reduces ischemic attacks in patients with stable angina: A prospective, multicenter, open-label, randomized, controlled study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01396395. Randomized; no masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2016-04-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina
- Acronym
- SIGMART
- Condition
- Stable Angina
- Condition
- Coronary Disease
- Intervention (Drug)
- Nicorandil
- Intervention (Drug)
- Standard Treatment
- Lead sponsor
- Merck KGaA, Darmstadt, Germany
- Collaborator
- Merck Serono Co., Ltd., China
Record details
- Record id
cardio:ct-nct01396395- Content hash
18d0692890ea86a04a1b6fe64e466580c6083106ef7cfac7bdd87c5dcfc3603b